3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1/2
3
Phase 2
2
Phase 1
1
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
2
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
242
Carboplatin
135
Nivolumab
132
Gemcitabine
127
Paclitaxel
116
Cisplatin
105
Bevacizumab
95
Cyclophosphamide
93
Dexamethasone
78
Injections
75
Docetaxel
72
Pemetrexed
71
Fluorouracil
68
Capecitabine
65
Rituximab
61
Cetuximab
61
atezolizumab
60
130-nm albumin-bound paclitaxel
59
Oxaliplatin
58
Leucovorin
56
Ipilimumab
54
fludarabine
47
Lenalidomide
47
Azacitidine
40
Irinotecan
39
venetoclax
38
Fulvestrant
38
Albumin-Bound Paclitaxel
36
Prednisone
35
Trastuzumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
R-CHOP protocol
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-05-05
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled